|Bid||2.4300 x 0|
|Ask||2.4400 x 0|
|Day's Range||2.4000 - 2.5200|
|52 Week Range||0.8700 - 4.3500|
|Beta (3Y Monthly)||3.98|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
After receiving the backing of Altria Group Inc (NYSE:MO), Canada-based cannabis producer Cronos Group (NASDAQ:CRON) looked like it was headed for significant growth, but it has not delivered. As a result, the performance of CRON stock has been disappointingSince the deal, CRON has not made meaningful strides in production, which is the name of the game in cannabis, nor has the company expanded notably overseas. Without even factoring in the valuation of CRON stock, I have serious concerns about the company.CRON just does not have strong enough fundamentals to propel Cronos stock meaningfully higher. The company continues to lag its competitors in production, R&D, and new markets.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Could Be Takeover Targets Capacity WoesCronos' production capacity is comparable to the likes of Organigram and CannTrust Holdings (NYSE:CTST), but the market gives CRON stock a substantially larger valuation.However, it is not clear why that gap is justified, since CRON is a less efficient grower and seller than its two competitors.Cronos, Organigram, and CannTrust Holdings all have similar capacity now and similar estimated capacity next year. Looking at recent results, though, Cronos clearly grows cannabis less efficiently and sells it less effectively. Cronos sold just 1,111 kg of cannabis last year, while Organigram sold 4,248 kg and CannTrust sold over 3,000 kg.Cronos is falling behind tremendously. CRON Doesn't Have an Edge OverseasCRON's international push does not seem to be materially different or more successful than that of its peers. Most of its overseas partnerships are in very competitive areas. Other players have been expanding much more aggressively, and CRON has less ground cultivated overseas than the competition, which will be a hindrance to its growth and to CRON stock.In Australia, for example, Cronos is aiming for annual production capacity of 2,000 kg. But that is peanuts compared to what Solaris Nutraceuticals Pty Ltd is doing. Its greenhouse will produce around 100,000 kg per year of medical cannabis.In Latin America, CRON has a 50/50 joint venture with AGI, Colombia's leading agricultural services provider. However, there has been a big increase in the number of cultivators in the region. Again, just as an example. AGI's 207 acres of available land pales in comparison to competitors like Colombia's Pharmacielo, which has over 15 million square feet of land. That translates roughly to production capacity of over 5,000 kilograms.There's also Khiron, a Colombian grower that has been expanding its own cultivation area. Its total area is estimated to be capable of producing 100,000 kilograms of dry flower for extraction and processing into medical cannabis.You get the idea.Europe is even more crowded. Germany and Poland, where many American-listed Canadian companies have been active in M&A and expanding their footprints, are particularly competitive. The Bottom Line on CRON StockThe cannabis industry is a very attractive space to be in, but there are bound to be some duds. At the moment, Cronos Group stock is shaping up to be a good name to short. One caveat is that Cronos does has a decent cash balance.Overall, investors can always generate profits by reducing exposure to the laggards and doubling down on the leaders. Investors should be reducing their exposure to CRON stock.As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding Compare Brokers The post Cronos Stock Is Lagging Other Marijuana Names appeared first on InvestorPlace.
High Tide (CSE: HITI) (OTCQB: HITIF) (FRA: 2LY) has opened a new Smoker's Corner retail store in the Royal Chapelle Area of Edmonton in Edmonton, Alberta. The Royal Chapelle Store will be supplied from the company's vast catalog of more than 4,300 SKUs of smoking accessories and cannabis lifestyle products, including the full range of proprietary […]The post Cannabis Stock News Daily Roundup June 5 appeared first on Market Exclusive.
Khiron Life Sciences Corp (OTCMKTS:KHRNF) has announced the completion of construction and the start of operations for growing, extraction and processing in the Ibague Colombia facility. Progress has been made regarding commercial registration as well as the production of medical cannabis products that target over 6 million patients in Latin America . Milestones and progress […]The post Khiron Announces Completion Of Ibague Colombia Facility appeared first on Market Exclusive.
Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF), a cannabis company with core operations in Latin America, said that it has been added the MJ ETFMG Alternative Harvest ETF (NYSE: MJ), a fund with approximately US$1.22 billion in assets currently under management. The company calls it an important development as it advances its strategy as a […]The post Khiron Life Sciences Added to ETFMG Alternative Harvest ETF appeared first on Market Exclusive.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Panaxia Pharmaceutical Industries Israel and pharmaceutical company Rafa signed a collaboration agreement with PlantEXT Ltd., an Israeli-Canadian medical cannabis company. Under the agreement, the parties will co-develop the next generation of medical cannabis products intended for patients suffering from Inflammatory Bowel Disease, and who are authorized to receive treatment with medical cannabis. Khiron Life Sciences (TSXV: […]The post Cannabis Stock News Daily Roundup May 1 appeared first on Market Exclusive.
Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) has entered into a non-binding letter of agreement to acquire 100% of the outstanding securities of Canapalife S.r.l. and a 100% stake interest in Campodoro S.r.l. – collective Canapalife Group – from shareholders Alvaro Garro and Paolo Puggioni. Khiron Seeking Opportunities in Europe Canapalife is a prominent hemp […]The post Khiron Life Sciences to Acquire Italian Hemp Company appeared first on Market Exclusive.
Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) has entered into an agreement with the prominent Colombian research hospital Centro Dermatológico Federico Lleras Acosta (CDFLLA) to test the effectiveness of medical cannabis for dermatological conditions. Cannabis for Skin Care Under the agreement, Khiron and CDFLLA will establish a clinical research partnership focused on the […]The post Khiron, Colombian Hospital to Clinically Test Cannabis for Dermatological Conditions appeared first on Market Exclusive.
Crop Infrastructure (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) has started the application process for its two retail applications for its Emerald Heights brand in California, one in Chula Vista and the other in Contra Costa. Cannvas MedTech (CSE: MTEC) (Frankfurt: 3CM) (OTCPK: CANVF) has formed a partnership with California-based interactive customer-focused cannabis education platform Seed Technology […]The post Cannabis Stock News Daily Roundup April 12 appeared first on Market Exclusive.
Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) has signed deals with two consumer distribution companies, Fedco and Linio, to sell its Kuida cosmeceutical brand in Colombia. Fedco is one of the largest beauty retailers in Colombia, while Linio is the online store in Latin America with more than 600,000 visits monthly and a presence in […]The post Khiron Finds Retail Partners in Colombia for CBD Skin Care Range appeared first on Market Exclusive.
Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF), a Canada-based company looking to become a dominant integrated cannabis company in Latin America, has signed multi-channel distribution agreements for its Kuida cosmeceutical brand with Fedco and Linio, two consumer distribution channels for wellness and beauty products in Colombia. Abattis Bioceuticals (CSE: ATT) (OTC: ATTBF) said its 1185277 […]The post Cannabis Stock News Daily Roundup April 3 appeared first on Market Exclusive.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! A look at the shareholders of KhironRead More...
Medical cannabis firm Khiron Life Sciences (OTCQB: KHRNF) announced that its subsidiary Kuida Life Mexico S.A. received approval from Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS) to import and commercialize three products of the company’s Nutraceutical Line. The approved initial products include; a CBD (cannabidiol) based formulation designed to help promote sleep; […] The post Khiron Life Nears Launching Nutraceutical Products in Mexico appeared first on Market Exclusive.
The funds will serve as general working capital and support cultivation expansion and asset acquisition. “With this capital raise, additional access to growth capital and key strategic partnerships in place, GrowForce is well-positioned to consolidate a fragmented cannabis industry in Canada and international markets,” James Lowe, executive vice president of operations for GrowForce, said in a statement. Aurora Cannabis Inc (TSE: ACB)(OTC: ACBFF) announced it signed a letter of intent to acquire the cannabis business of HotHouse Consulting Inc., which supports about 50 customers globally.